Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., continues due diligence toward an agreement to help develop a promising new treatment for Traumatic Brain Injury (TBI), concern continues to grow over the troubling incidence of TBI among athletes and soldiers.
The recent, tragic death of NFL great Junior Seau has led to intense speculation that the linebacker suffered from TBI inflicted on the gridiron. Even more disheartening is the number of American war veterans complaining of symptoms as they return from Afghanistan. In recent years, more than 200,000 troops have tested positive for traumatic brain injuries, including concussions.
Currently, TBI and other neuropathic maladies can only be diagnosed after death, leaving many soldiers and athletes to wonder if they have it or not. RBCC hopes to help change that.
The company is currently negotiating a potential joint venture with Amarantus BioSciences (OTCBB: AMBS). AMBS is a biotech firm that has developed a therapeutic protein known as MANF to treat disorders associated with endoplasmic reticulum stress, including traumatic brain injury.
If a definitive agreement is reached, RBCC will help AMBS secure funding to continue their research and development process on a mission to bring a potent new weapon against TBI and other brain afflictions to a global healthcare market hungry for solutions.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.